Navamedic ASA completed the acquisition of marketing authorisations for antibiotics in the Nordics
Oslo, 4 August 2020 – Navamedic ASA (“Navamedic”, OSE: NAVA), today announces it has completed the transaction with ACS Dobfar and InfoRLife for the acquisition of marketing authorisations for a series of antibiotics for hospital use in the Nordic region. Navamedic acquires the marketing authorisations for a total consideration of up to NOK 38 million. Reference is made to Navamedic’s announcement on 7 February 2020 about the acquisition of a series of antibiotics for hospital use in the Nordic region from ACS Dobfar and its subsidiary InfoRLife. The transaction is now completed,